DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
BDX logo

Becton, Dickinson and Company Stock Price

NYSE:BDX Community·US$48.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 57 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BDX Share Price Performance

US$179.80
-8.63 (-4.58%)
​
US$195.67
Fair Value
US$179.80
-8.63 (-4.58%)
8.1% undervalued intrinsic discount
US$195.67
Fair Value
Price US$179.80
AnalystConsensusTarget US$195.67
AnalystLowTarget US$170.00
AnalystHighTarget US$216.80
Sat, 5 Sep 26
Fair ValueUS$195.67
Share Pricen/a

BDX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$195.67 8.1% undervalued intrinsic discount

Advanced Diagnostics And Tissue Regeneration Will Expand Decentralized Healthcare

0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$170 5.8% overvalued intrinsic discount

Life Sciences Margins Will Fall As Global Research Funding Declines

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$216.8 17.1% undervalued intrinsic discount

Global Aging And Digital Health Trends Will Transform Patient Care

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
BDX logo
Becton Dickinson
8.1% undervalued intrinsic discount
Updated

Advanced Diagnostics And Tissue Regeneration Will Expand Decentralized Healthcare

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 5 Sep
Read Narrative
BDX logo
Becton Dickinson
5.8% overvalued intrinsic discount

Life Sciences Margins Will Fall As Global Research Funding Declines

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 22 Aug
Read Narrative
BDX logo
Becton Dickinson
17.1% undervalued intrinsic discount

Global Aging And Digital Health Trends Will Transform Patient Care

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 22 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
BDX logo

BDX: Margin Execution And Capital Returns May Balance 2027 Utilization Concerns

Fair Value: US$195.67 8.1% undervalued intrinsic discount
24 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
BDX logo

BDX: 2027 Utilization And Inflation Headwinds Will Cap Medium Term Upside

Fair Value: US$170 5.8% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
BDX logo

BDX: Raised FY26 EPS Guidance And Buybacks Will Support Underappreciated Setup

Fair Value: US$216.8 17.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Established dividend payer and good value.

2 Risks
4 Rewards
View Full Analysis

Becton, Dickinson and Company Key Details

US$22.5b

Revenue

US$11.9b

Cost of Revenue

US$10.6b

Gross Profit

US$8.9b

Other Expenses

US$1.6b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
6.05
46.94%
7.33%
68.8%
View Full Analysis

About BDX

Founded
1897
Employees
72000
CEO
Thomas Polen
WebsiteView website
www.bd.com

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Recent BDX News & Updates

User avatar
Narrative Update • Sep 05

BDX: Margin Execution And Capital Returns May Balance 2027 Utilization Concerns

Becton Dickinson's updated fair value estimate of about $196, compared with roughly $190 previously, reflects analysts' higher price targets in the $190 to $210 range and their focus on remaining margin opportunity, manufacturing scale, and potential for steadier mid single digit growth over time. Analyst Commentary Recent research on Becton Dickinson shows a mix of optimism and caution that centers on execution, margin potential, and how quickly growth goals can show up in reported results.

Recent updates

No updates

Becton, Dickinson and Company Competitors

UNH logo

UnitedHealth Group

Symbol: NYSE:UNH
Market cap: US$359.8b
ABT logo

Abbott Laboratories

Symbol: NYSE:ABT
Market cap: US$182.6b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$123.7b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$122.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide